How do movement disorders clinic nurses explain to a Spanish-speaking Parkinson's patient why stopping carbidopa-levodopa does not reveal a milder disease but removes the floor that was holding motor function up?

The Parkinson's patient who has stopped or dramatically reduced carbidopa-levodopa after reading or hearing that the medication causes tremors has made a logical inference from a false premise. The movement disorders clinic nurse's explanation must correct the misunderstanding about what the medication does before addressing the clinical consequences of stopping it. Carbidopa-levodopa does not cause rest tremors. The medication replaces dopamine: the levodopa crosses the blood-brain barrier and is converted to dopamine in the surviving neurons of the substantia nigra and the striatum. The carbidopa component prevents levodopa from being converted to dopamine in the bloodstream before it reaches the brain, reducing peripheral side effects and increasing the brain-available dose. The effect is that the dopamine-depleted striatum receives a pharmacological restoration of the signal that the dying nigral neurons can no longer supply in adequate quantity. The motor function the patient experiences on medication — reduced rigidity, improved gait speed, reduced bradykinesia — is produced by this restored signal, not by spontaneous disease remission. When the medication is stopped, the signal is removed. The motor function returns to the level the surviving nigral neurons can sustain without supplementation, which in a patient who has had Parkinson's disease for several years is substantially below the medicated level. This does not reveal a milder underlying disease. It removes the pharmacological floor. The tremors the patient read about in the Facebook group were almost certainly peak-dose dyskinesia — an entirely different movement from Parkinson's rest tremor. Peak-dose dyskinesia consists of involuntary writhing or twisting movements that occur when the levodopa level in the brain is at its highest point (approximately 60–90 minutes after a dose), when the dopamine receptor sensitization that develops after years of medication produces an overshoot. This is a sign of too much dopamine at peak, not of the medication causing tremors — and it is managed by distributing the dose differently across the day, not by stopping. In Spanish: 'La pastilla no le da los temblores del Parkinson. Lo que hace es reponer la dopamina que la enfermedad destruyó. Los temblores que le causaron preocupación en ese grupo — esos son un efecto diferente que se llama discinesia, que ocurre cuando el nivel de la pastilla está muy alto en el momento que hace efecto máximo. Eso se maneja ajustando la dosis. Cuando usted dejó de tomar la pastilla, no apareció una enfermedad más leve — lo que pasó fue que el nivel de dopamina bajó al nivel que sus neuronas restantes pueden producir solas, que después de ocho años de Parkinson ya no es suficiente para sostener la función que usted tenía. Las dos caídas del mes pasado son la manifestación de eso. La buena noticia es que eso es reversible: al reintroducir la medicación con el esquema correcto, la función regresa.' (The pill does not give you Parkinson's tremors. What it does is replenish the dopamine the disease destroyed. The tremors that caused concern in that group — those are a different effect called dyskinesia, which occurs when the pill's level is very high at the moment it peaks. That is managed by adjusting the dose. When you stopped taking the pill, a milder disease did not appear — what happened was that the dopamine level dropped to the level your remaining neurons can produce on their own, which after eight years of Parkinson's is no longer enough to sustain the function you had. The two falls last month are the manifestation of that. The good news is that it is reversible: when the medication is reintroduced on the correct schedule, the function returns.)

How do movement disorders clinic nurses explain to a Spanish-speaking essential tremor patient why his medication is helping even though his tremor feels worse than he remembers it being?

The essential tremor patient who believes his medication is making things worse is usually experiencing a comparison baseline problem rather than a true medication failure. The movement disorders clinic nurse's explanation must first establish what the correct comparison is before discussing whether the medication is working. Essential tremor is a progressive condition — in most patients, the amplitude and frequency of tremor increase over time without treatment. A patient who has had essential tremor for fifteen or twenty years and starts medication at age seventy-three is comparing his current tremor not to his tremor three months ago when treatment began but to his memory of how his hands were when the tremor was first noticed, which may be a decade or more earlier when the disease was less advanced. The objective baseline is what was documented at intake. If the intake note documented inability to sign a legible name, difficulty pouring liquids, and a validated tremor scale score of 28, and the patient today can sign his name and his tremor scale score is 24, the medication is working — but his subjective experience is that he is worse because his mental comparison is to the best years rather than to the worst month. Additionally, primidone in particular has an adjustment period that is consistently the most difficult phase of treatment: primidone metabolizes to phenobarbital, which causes sedation, unsteadiness, and sometimes increased tremor amplitude in the first two to four weeks as the nervous system adapts. Patients who stop medication during this adjustment phase often stop exactly when the pharmacological benefit was about to emerge. The clinical approach is to show the patient the objective data: the written record of what was measured before treatment started, compared to what is measured today, and what the expected trajectory is at the full therapeutic dose (which in primidone may not be reached for three to six months of gradual titration). In Spanish: 'Entiendo que siente que sus manos tiemblan más que lo que recuerda. Pero lo que recordamos de hace cinco años no es la misma cosa que lo que midió el médico el día que empezamos el tratamiento. Eso fue hace tres meses — y lo que está escrito en ese registro es lo que tenemos que comparar con hoy. Cuando el doctor midió su temblor en la primera cita, anotó que no podía firmar su nombre en forma legible. Hoy su firma es legible. La medicación está funcionando. Lo que siente es que no está donde estaba hace diez años — y eso es correcto. La medicación no revierte diez años de progresión; reduce el temblor desde donde está ahora. Y también, la dosis que usted toma hoy es una fracción de la dosis que produce el beneficio máximo. Vamos a subir la dosis gradualmente durante los próximos dos meses — el beneficio completo todavía no ha llegado.' (I understand that you feel your hands shake more than you remember. But what we remember from five years ago is not the same thing as what the doctor measured on the day we started treatment. That was three months ago — and what is written in that record is what we need to compare with today. When the doctor measured your tremor at the first appointment, it was noted that you could not sign your name legibly. Today your signature is legible. The medication is working. What you feel is that you are not where you were ten years ago — and that is correct. The medication does not reverse ten years of progression; it reduces the tremor from where it is now. And also, the dose you are taking today is a fraction of the dose that produces the maximum benefit. We are going to increase the dose gradually over the next two months — the full benefit has not yet arrived.)

How do movement disorders clinic nurses explain deep brain stimulation to Spanish-speaking patients and family members who believe the device has stopped working because Parkinson's symptoms are returning?

The family of a Parkinson's patient with deep brain stimulation who sees motor symptoms returning after an initial period of excellent control commonly interprets this as device failure — the machine broke, the battery died, or the leads moved. The movement disorders clinic nurse's explanation must first establish what DBS actually does before distinguishing between device failure and disease progression requiring programming adjustment. DBS does not stop Parkinson's disease. It delivers continuous high-frequency electrical pulses (typically 130 to 185 Hz) to a specific target in the basal ganglia — usually the subthalamic nucleus, or STN — that modulate the pathological overactivity that the diseased basal ganglia circuit produces. In Parkinson's disease, the loss of dopaminergic input from the substantia nigra causes the indirect pathway of the basal ganglia to become overactive, which excessively inhibits the thalamus, which reduces the smooth voluntary movement signals reaching the motor cortex. DBS applied to the STN suppresses that excessive indirect pathway activity, allowing the thalamus to function more normally and restoring smoother voluntary movement. This is a circuit modulation. The disease itself — the progressive loss of nigral neurons, the spread of alpha-synuclein pathology to other brain regions, the development of axial symptoms and cognitive changes — continues independently of the DBS. At the same time that DBS was improving motor control in the months after implant, the disease continued to progress. After two years, the stimulation parameters that produced excellent control when first programmed may no longer be sufficient for the current disease stage. Device interrogation can confirm battery level, lead impedance, and whether stimulation is being delivered — and when those parameters are normal, the conclusion is not device failure but disease progression requiring parameter adjustment. Programming is not a one-time calibration; it is an ongoing process of matching the stimulation intensity and configuration to the current state of the disease. In Spanish: 'El aparato no dejó de funcionar. Cuando revisamos el aparato hoy, la batería está al sesenta y ocho por ciento, los cables están transmitiendo normalmente, y la estimulación está llegando a donde debe llegar. Lo que pasó es que el Parkinson siguió avanzando durante los dos años desde la cirugía. El DBS no detiene el Parkinson — modula un circuito en el cerebro que está funcionando de forma anormal. Hace dos años, los parámetros que programamos producían un control excelente porque coincidían con el estado de la enfermedad en ese momento. La enfermedad siguió su curso. Los parámetros que funcionaban bien hace dos años ya no son suficientes para el estado actual. Lo que necesitamos no es reparar el aparato sino actualizar la programación. Es como cuando uno necesita lentes nuevos porque la visión cambió — el ojo no dejó de funcionar, pero la graduación que servía antes ya no sirve para la vista de hoy. Vamos a programar una cita de programación en dos semanas donde el neurólogo va a ajustar los parámetros.' (The device did not stop working. When we check the device today, the battery is at 68 percent, the leads are transmitting normally, and the stimulation is reaching where it should reach. What happened is that Parkinson's continued to progress during the two years since surgery. DBS does not stop Parkinson's — it modulates a circuit in the brain that is functioning abnormally. Two years ago, the parameters we programmed produced excellent control because they matched the state of the disease at that time. The disease continued its course. The parameters that worked well two years ago are no longer sufficient for the current state. What we need is not to repair the device but to update the programming. It is like when you need new glasses because your vision changed — the eye did not stop working, but the prescription that worked before no longer works for today's vision. We are going to schedule a programming appointment in two weeks where the neurologist will adjust the parameters.)

How do movement disorders clinic nurses explain the difference between Parkinson's rest tremor and peak-dose dyskinesia to Spanish-speaking patients who confuse the two?

Parkinson's rest tremor and peak-dose dyskinesia look different on examination but can both be described as 'los temblores' (the shakes) by patients and family members who have not been taught the clinical distinction. The movement disorders clinic nurse's explanation must make the functional distinction concrete and demonstrate it in the encounter. Rest tremor in Parkinson's disease is a rhythmic, low-frequency oscillation (4 to 6 Hz) that occurs when the affected limb is relaxed and not being used — the classic 'pill-rolling' of the thumb and forefinger, or the hand shaking while resting on the lap, that characteristically stops or diminishes when the patient reaches to pick up a glass. It is produced by the abnormal activity in the basal ganglia-thalamic circuit that occurs in the absence of dopamine. It is most prominent during rest and typically suppressed during voluntary movement. Peak-dose dyskinesia is an entirely different movement: irregular, flowing, writhing, or twisting movements of the trunk, limbs, or face that occur approximately 45 to 90 minutes after a dose of carbidopa-levodopa, when the brain dopamine level is highest. They are produced not by dopamine deficiency but by dopamine receptor supersensitivity that develops after years of pulsatile dopamine replacement — the sensitized receptors overshoot when the levodopa level peaks. Dyskinesia is not a sign that the medication is wrong; it is a sign that the peak dose is slightly too high for the current receptor sensitivity, and the management is dose distribution (smaller, more frequent doses or adding a COMT inhibitor to smooth the pharmacokinetic curve), not medication discontinuation. In Spanish: 'Los temblores del Parkinson y la discinesia se ven diferente. Los temblores del Parkinson ocurren cuando el brazo está quieto y descansado — cuando el paciente está sentado sin hacer nada, la mano empieza a temblar. Cuando intenta agarrar algo — cuando hay movimiento voluntario — el temblor para o disminuye. La discinesia es diferente: son movimientos que se ven como ondulaciones o contorsiones irregulares, y ocurren cuando el nivel de la pastilla está en su punto más alto, unos cuarenta y cinco a noventa minutos después de la dosis. No son iguales, aunque los dos se llamen temblores en el lenguaje cotidiano. Los temblores del Parkinson son una señal de que la dopamina está baja. La discinesia es una señal de que el pico de la dopamina está un poco alto para los receptores de este paciente en este momento. Uno se trata con más medicación; el otro se trata con ajuste de la dosis — pero no con parar.' (Parkinson's tremors and dyskinesia look different. Parkinson's tremors occur when the arm is still and resting — when the patient is sitting doing nothing, the hand starts to shake. When trying to grab something — when there is voluntary movement — the tremor stops or decreases. Dyskinesia is different: it consists of movements that look like waves or irregular twisting, and they occur when the pill's level is at its highest point, approximately 45 to 90 minutes after a dose. They are not the same, even though both are called tremors in everyday language. Parkinson's tremors are a signal that dopamine is low. Dyskinesia is a signal that the dopamine peak is slightly high for this patient's receptors at this moment. One is treated with more medication; the other is treated by adjusting the dose — but not by stopping.)

What are the key Spanish phrases movement disorders clinic nurses need for explaining dopamine replacement in Parkinson's disease, essential tremor medication evaluation, and deep brain stimulation programming?

Movement disorders clinic nurses working with Spanish-speaking patients across Parkinson's disease, essential tremor, and DBS management need a core set of phrases for the specific explanations these encounters require. For carbidopa-levodopa and dopamine replacement: 'La pastilla repone la dopamina que la enfermedad destruyó — no cura el Parkinson, pero mantiene el nivel de dopamina que sus neuronas ya no pueden producir solas' (The pill replenishes the dopamine the disease destroyed — it does not cure Parkinson's, but it maintains the dopamine level that your neurons can no longer produce on their own); 'Cuando deja de tomar la pastilla, no aparece una enfermedad más leve — el nivel de dopamina baja al nivel que queda sin la pastilla, que después de varios años de Parkinson ya no es el mismo nivel que tenía antes del diagnóstico' (When you stop taking the pill, a milder disease does not appear — the dopamine level drops to the level that remains without the pill, which after several years of Parkinson's is no longer the same level you had before diagnosis); 'Los movimientos ondulantes que vio en el video no son los temblores del Parkinson — se llaman discinesia, y ocurren cuando el nivel de la pastilla está muy alto, no cuando está muy bajo' (The wave-like movements you saw in the video are not Parkinson's tremors — they are called dyskinesia, and they occur when the pill's level is too high, not when it is too low). For essential tremor medication: 'La comparación correcta es con cómo estaban sus manos el día que empezamos el tratamiento — no con cómo estaban hace cinco años' (The correct comparison is with how your hands were on the day we started treatment — not with how they were five years ago); 'La primidona tiene un período de adaptación de dos a cuatro semanas en que el cuerpo se ajusta y algunos pacientes sienten más inestabilidad — ese período ya pasó, y lo que medimos hoy muestra mejoría' (Primidone has an adjustment period of two to four weeks when the body adapts and some patients feel more unsteadiness — that period has passed, and what we measure today shows improvement); 'La dosis actual es una fracción de la dosis terapéutica completa — el beneficio máximo llega cuando terminamos la titulación' (The current dose is a fraction of the full therapeutic dose — the maximum benefit arrives when we finish the titration). For DBS: 'El DBS modula un circuito cerebral que está hiperactivo — no detiene el Parkinson, y la enfermedad sigue su curso en otros sistemas' (DBS modulates a brain circuit that is overactive — it does not stop Parkinson's, and the disease continues its course in other systems); 'El aparato está funcionando normalmente — lo que cambió es que la enfermedad avanzó y la programación necesita actualizarse para el estado actual' (The device is functioning normally — what changed is that the disease advanced and the programming needs to be updated for the current state); 'La programación del DBS no es una calibración única — se ajusta periódicamente a medida que la enfermedad evoluciona' (DBS programming is not a one-time calibration — it is adjusted periodically as the disease evolves).

Spanish for movement disorders clinic nurses — the Parkinson’s patient who stopped carbidopa-levodopa because he believed the medication was causing his tremors, the essential tremor patient convinced primidone is making his hands worse because he is comparing to five years ago rather than last month, and the DBS patient whose daughter has decided the device stopped working because the symptoms she saw before implant are back

The movement disorders clinic sees a patient who stopped a medication that was working because he read online that it caused the exact symptom it was treating. He is a careful person — he did not stop abruptly; he tapered over three months. He presented the information to his family as a reasonable decision. He cannot understand why his gait has deteriorated and why he fell twice last month, because in his model the medication was not helping — the medication was the problem. What he encountered on that Facebook group was a description of peak-dose dyskinesia, translated into everyday Spanish as “los temblores,” and he recognized the word without recognizing that the phenomenon was entirely different from his disease.

The clinic also sees the patient with essential tremor who is convinced his medication is making his hands worse. His evidence is real: his hands shake. His comparison is also real: he remembers a time when they shook less. The problem is that the baseline he is comparing to is how his hands felt at their best, years before treatment, when the disease was less advanced — not how his hands were at the intake visit three months ago, when the medication was started because the disease had already progressed to that level. The medication did not produce the current tremor. The current tremor is where the disease was when treatment started. The medication reduced it from where it was at that point, not from the best year he can recall.

And the clinic sees the family of a patient with Parkinson’s disease and a deep brain stimulator, arriving with a written list of symptoms that have returned and a conviction that the device is broken. The device is not broken. The battery is at sixty-eight percent. The lead impedances are normal. What happened is that the disease progressed, as Parkinson’s disease does, and the stimulation parameters that produced excellent control at initial programming two years ago are no longer sufficient for the current disease stage. The device is doing exactly what it was designed to do. The disease has moved past what those parameters were calibrated for.

These three failure modes are structurally identical. None of them involves a patient who is deliberately non-adherent or who distrusts the clinic. All three involve a working conceptual model of the disease and its treatment that has a specific gap — a gap that generates a reasonable-sounding conclusion from incorrect premises. The movement disorders clinic nurse who can explain the distinction between rest tremor and peak-dose dyskinesia, the difference between subjective memory and objective baseline, and the distinction between disease progression and device failure closes those gaps before the patient deteriorates further or loses confidence in a treatment that is working.

Ernesto Vásquez, 67, San Bernardino — four months of self-reduced carbidopa-levodopa and two falls

Ernesto Vásquez is 67 years old, a retired machinist from San Bernardino who was diagnosed with Parkinson’s disease eight years ago. He has been on carbidopa-levodopa 25/100 three times daily for five years, with good motor control at last evaluation: his MDS-UPDRS Part III motor examination score was 22 out of 108, indicating mild motor impairment on medication. He is enrolled in a weekly group exercise program. He has been driving without incident until six weeks ago.

Four months ago, Ernesto found a Spanish-language health video on Facebook that featured a man describing how the “pastilla para el Parkinson” made his shaking worse. The comments section included several responses from other users describing similar experiences. Ernesto shared the video with his brother, who agreed that stopping a medication that was causing the problem made sense. Ernesto reduced his dose gradually — from three tablets daily to two over six weeks, then to one over the following six weeks. He did not tell the clinic.

At today’s visit, movement disorders clinic nurse Isabel Cruz notices immediately that Ernesto is moving more slowly than at his last appointment. His facial expression is reduced. His right arm barely swings. He tells her before she asks: he has been taking less of the medication, he has had two falls, and he wants to explain his reasoning before she says anything.

Isabel listens to the full explanation before responding.

“Señor Ernesto, hizo bien en contarme. Antes de hablar de cómo vamos a volver al esquema original, quiero explicarle qué vio en ese video — porque lo que esas personas describían no era lo mismo que sus temblores, aunque usaron la misma palabra.”

(You did well in telling me. Before we talk about how we are going to return to the original schedule, I want to explain to you what you saw in that video — because what those people were describing was not the same as your tremors, even though they used the same word.)

Isabel picks up a pen and draws a simple timeline on the exam paper: a horizontal axis marked from zero to four hours, representing the time after a dose of carbidopa-levodopa. She marks a curve rising from zero, reaching a peak at sixty to ninety minutes, then falling.

“Cuando usted toma la pastilla, el nivel de la medicación en el cerebro sube y baja durante el día. En el punto más alto — una hora, una hora y media después de la dosis — algunas personas que llevan muchos años con la medicación empiezan a tener un movimiento diferente: no temblores como los del Parkinson, sino movimientos ondulantes, de contorsión, que ocurren justo en ese momento del pico. Eso se llama discinesia. No es un temblor — es lo contrario de un temblor en términos del mecanismo. Los temblores del Parkinson ocurren cuando hay poca dopamina. La discinesia ocurre cuando hay demasiada en ese pico.”

(When you take the pill, the medication level in the brain rises and falls during the day. At the highest point — one hour, an hour and a half after the dose — some people who have been on the medication for many years start to have a different movement: not tremors like Parkinson’s ones, but wave-like, twisting movements that occur exactly at that peak moment. That is called dyskinesia. It is not a tremor — it is the opposite of a tremor in terms of mechanism. Parkinson’s tremors occur when there is little dopamine. Dyskinesia occurs when there is too much at that peak.)

She asks Ernesto to recall the specific movement the man in the video was making. He describes it: the man’s head was moving from side to side, his arms making slow, flowing motions while he was sitting. Isabel confirms: that is dyskinesia, not Parkinson’s rest tremor. She asks Ernesto to describe his own tremor: when does it happen? He describes it correctly — his right hand shakes when it is resting on his lap, and it stops when he reaches to pick something up. That is rest tremor: it occurs at rest and diminishes with voluntary movement. The two phenomena look different, occur at different times in the medication cycle, and have opposite underlying mechanisms.

“Lo que esas personas necesitaban era un ajuste de dosis — dosis más pequeñas repartidas con más frecuencia para suavizar el pico. No necesitaban parar. Y usted, si alguna vez empieza a tener ese movimiento, me llama y hacemos ese ajuste. Pero ese no es el problema que tiene hoy.”

(What those people needed was a dose adjustment — smaller doses spread more frequently to smooth the peak. They did not need to stop. And you, if you ever start to have that movement, call me and we make that adjustment. But that is not the problem you have today.)

Now Isabel addresses why reducing the medication produced what Ernesto is experiencing. She explains the mechanism directly.

“El Parkinson destruye las neuronas que producen dopamina en un área del cerebro llamada sustancia negra. La dopamina es la señal que le dice al cerebro cómo iniciar y regular el movimiento. Con el tiempo, esas neuronas se van reduciendo y el cerebro produce cada vez menos dopamina. La pastilla reemplaza lo que esas neuronas ya no pueden producir. Cuando usted la tomaba tres veces al día, el nivel de dopamina se mantenía en un rango donde su cerebro podía controlar el movimiento. Cuando bajó la dosis a una vez al día, ese nivel cayó por debajo del umbral. La rigidez, la lentitud, la caída en el giro — eso no es la enfermedad revelando lo que siempre fue. Eso es lo que pasa cuando se quita el suelo que estaba sosteniendo la función.”

(Parkinson’s destroys the neurons that produce dopamine in a brain area called the substantia nigra. Dopamine is the signal that tells the brain how to initiate and regulate movement. Over time, those neurons diminish and the brain produces less and less dopamine. The pill replaces what those neurons can no longer produce. When you were taking it three times a day, the dopamine level stayed in a range where your brain could control movement. When you reduced the dose to once a day, that level fell below the threshold. The rigidity, the slowness, the fall on the turn — that is not the disease revealing what it always was. That is what happens when you remove the floor that was holding the function up.)

Ernesto asks the question Isabel expected: “¿Y si lo vuelvo a tomar, las funciones que perdí regresan?” (And if I take it again, will the functions I lost come back?)

“Sí. No de un día para otro, pero en dos a tres semanas de vuelta al esquema original, la función debe regresar al nivel que tenía antes de reducir la dosis. El daño que le preocupaba — la idea de que la pastilla estaba haciendo algo permanente — no ocurrió. Lo que pasó es reversible.”

(Yes. Not overnight, but in two to three weeks back on the original schedule, the function should return to the level you had before reducing the dose. The damage you were worried about — the idea that the pill was doing something permanent — did not happen. What happened is reversible.)

Isabel restarts carbidopa-levodopa 25/100 three times daily with a titration schedule that returns to the full dose over ten days to minimize adjustment effects. She refers Ernesto to physical therapy for fall risk rehabilitation and requests a family education session for his brother. She documents the dyskinesia video misunderstanding in the chart and adds a patient education note explaining the distinction, to be reviewed at every visit.

At the three-week follow-up, Ernesto’s MDS-UPDRS motor score is 24 — two points above his pre-reduction baseline, which is within normal clinical variation. His gait is fluid. He is driving again. “Me explicó que no son lo mismo los dos tipos de temblores. Eso era lo que me faltaba entender.”

Roberto Méndez, 73, San Antonio — essential tremor, primidone, and the wrong comparison baseline

Roberto Méndez is 73 years old, a former postal worker from San Antonio with essential tremor for twenty years. His tremor is bilateral, affecting the hands and mildly the head, with moderate functional impact: he cannot sign his name legibly, has difficulty pouring liquids without using both hands, and stopped eating soup in restaurants six years ago because of embarrassment. His ETRS (Essential Tremor Rating Scale) score at intake three months ago was 28 out of 64, in the moderate range.

He was started on primidone 50 mg at bedtime three months ago with a titration plan: 50 mg for four weeks, then 100 mg, then 150 mg at eight weeks, targeting 250 mg in divided doses by week twelve if tolerated. He is currently at 100 mg daily — week eight of the protocol, the second titration step.

He arrives today and tells movement disorders clinic nurse Diego Vargas he wants to stop the medication. “Mis manos tiemblan igual o más que antes de empezar. No está funcionando.” (My hands shake the same or more than before I started. It is not working.)

Diego does not immediately disagree. He asks Roberto to describe what he means by “before I started” — what specific moment is he comparing to?

Roberto describes his hands as they were around age sixty-three, when he first noticed the tremor. “Tenía un temblor pequeño. Podía escribir. Ahora no.” (I had a small tremor. I could write. Now I cannot.)

Diego nods. “Eso fue hace diez años. El temblor esencial es progresivo — empeora con el tiempo sin tratamiento. La comparación que necesitamos hacer no es con hace diez años sino con hace tres meses, cuando tomé las medidas que están en este registro.”

(That was ten years ago. Essential tremor is progressive — it worsens over time without treatment. The comparison we need to make is not with ten years ago but with three months ago, when I took the measurements that are in this record.)

Diego opens the intake note on his tablet. He reads aloud: “Tremor severity at intake: unable to sign name legibly, requires both hands to pour liquids, ETRS score 28.” He asks Roberto to sign his name on the examination paper.

Roberto’s signature is shaky but identifiable. Diego holds the paper next to the intake documentation where Roberto’s previous attempt was recorded. The current signature is better.

“Lo que está haciendo la medicación no es devolverle las manos de hace diez años. Está reduciendo el temblor desde donde estaba hace tres meses cuando empezamos. Y hay otro problema: la dosis que está tomando ahora es solo el cuarenta por ciento de la dosis terapéutica. Todavía estamos en el proceso de subir la dosis gradualmente para que el cuerpo se adapte. El beneficio completo de la primidona llega cuando estamos en la dosis final — y todavía no llegamos.”

(What the medication is doing is not giving you back the hands of ten years ago. It is reducing the tremor from where it was three months ago when we started. And there is another problem: the dose you are taking now is only forty percent of the therapeutic dose. We are still in the process of gradually increasing the dose so the body adapts. The full benefit of primidone arrives when we are at the final dose — and we have not arrived there yet.)

Roberto says the first two weeks were particularly bad — he felt dizzy, his balance was off, and his hands felt worse than at any point he could remember. He almost stopped then.

Diego explains the adjustment biology directly. Primidone is converted in the liver to phenobarbital, which is a barbiturate with sedating and central nervous system-depressing properties. In the first two to four weeks of treatment, before the nervous system adapts to the phenobarbital, patients reliably experience sedation, unsteadiness, and sometimes increased tremor amplitude. This period is pharmacologically predictable and temporary. It resolves as the body reaches a new equilibrium with the drug. Roberto navigated the hardest part of the treatment and stopped measuring at exactly the moment the benefit was becoming visible.

“Las primeras dos semanas de primidona son las peores para casi todos. El cuerpo se está adaptando a la fenobarbital que produce la medicación. Eso mejora. Usted ya pasó esas semanas — lo difícil ya ocurrió. Lo que le estoy pidiendo ahora es que llegue a la dosis completa para que veamos el resultado real. No es justo medir la medicación a cuarenta por ciento de su dosis durante la peor semana de adaptación.”

(The first two weeks of primidone are the worst for almost everyone. The body is adapting to the phenobarbital that the medication produces. That improves. You already went through those weeks — the difficult part already happened. What I am asking you now is to reach the full dose so we can see the real result. It is not fair to measure the medication at forty percent of its dose during the worst week of adaptation.)

Diego shows Roberto the expected trajectory on a validated tremor scale — today’s score is 24, down from 28 at intake. At the target dose of 250 mg daily, the expected reduction from published clinical trial data is an additional 40 to 50 percent of tremor amplitude from baseline. Roberto’s baseline of 28 suggests an expected final score in the range of 15 to 18 at full dose — which translates, Diego explains, to what his hands were at around age sixty-eight, the last period he describes as functional.

“¿No a los sesenta y tres?” (Not to sixty-three?)

“No. La medicación reduce el temblor desde donde está ahora, no desde cuando empezó la enfermedad. Pero sesenta y ocho es cuando usted todavía podía tomar sopa en el restaurante sin preocuparse.”

(No. The medication reduces the tremor from where it is now, not from when the disease started. But sixty-eight is when you could still eat soup in the restaurant without worrying.)

Roberto is quiet for a moment. “El estimado de sesenta y ocho está bien.”

Diego continues the titration. At week twelve, Roberto is on 250 mg daily. His ETRS score at the twelve-week visit is 17. He arrives for that visit and places a Styrofoam cup of coffee from the clinic waiting room on the desk. He poured it himself, with one hand. “Eso no lo podía hacer en tres años.”

Luciana Herrera, 61, Los Angeles — DBS programming, disease progression, and the difference between a broken device and an outdated prescription

Luciana Herrera is 61 years old, a retired high school teacher from Los Angeles who was diagnosed with Parkinson’s disease eleven years ago. Her motor symptoms progressed despite optimized medical management. Two years ago she underwent bilateral subthalamic nucleus deep brain stimulation. The initial programming produced an excellent response: her MDS-UPDRS Part III motor score in the OFF-medication state fell from 42 to 19 at the six-week programming visit. She reduced her carbidopa-levodopa dose by thirty percent. She returned to gardening and weekly walks with her daughter Marisol.

Marisol has come to today’s visit with a notebook. She has been tracking symptoms for six weeks: right hand resting tremor two to three times per day, slowness getting up from chairs, reduced arm swing on the right, slightly softer voice in the evenings. She has written at the top of the first page: “El aparato dejó de funcionar.”

Movement disorders clinic nurse Ana Soto reads the notebook entry and does not contradict it immediately. She asks Marisol what she thinks should happen if the device has stopped working.

Marisol says the device should be replaced or repaired. She asks if a new surgery would be needed.

Ana says: “Antes de hablar de cirugía, necesito revisar el aparato. Eso me va a tomar dos minutos y nos va a decir exactamente qué está pasando.”

(Before we talk about surgery, I need to check the device. That will take me two minutes and will tell us exactly what is happening.)

Ana uses the DBS programmer to interrogate Luciana’s implant. She reads the results aloud as she goes: battery level sixty-eight percent, expected remaining life approximately three years at current settings. Lead impedances within normal range on all four contacts in both hemispheres. Stimulation amplitude at programmed settings: 3.0 volts, 60 microseconds pulse width, 130 Hz. All four contacts delivering stimulation normally.

“El aparato está funcionando exactamente como fue programado. La batería está al sesenta y ocho por ciento. Los cables transmiten normalmente. La estimulación está llegando a las dos partes del cerebro donde fue implantado. No hay ninguna señal de que el aparato haya fallado.”

(The device is functioning exactly as it was programmed. The battery is at 68 percent. The leads are transmitting normally. The stimulation is reaching both parts of the brain where it was implanted. There is no sign that the device has failed.)

Marisol points at the notebook. “Entonces, ¿por qué están volviendo los síntomas?” (Then why are the symptoms coming back?)

Ana sets down the programmer and gives the explanation the encounter requires. She draws the basal ganglia circuit on the exam paper — a simplified version: two boxes labeled “direct pathway” and “indirect pathway,” with arrows showing how each affects the thalamus and motor cortex.

“El DBS no detiene el Parkinson. El Parkinson destruye neuronas que producen dopamina. Eso sigue pasando, independientemente del DBS. Lo que hace el DBS es enviar impulsos eléctricos de alta frecuencia — ciento treinta veces por segundo — a una estructura dentro del cerebro llamada el núcleo subtalámico. Cuando el Parkinson destruye las neuronas de dopamina, ese núcleo se vuelve hiperactivo — dispara señales con demasiada frecuencia, y eso suprime el movimiento voluntario. Los impulsos del DBS apagan esa hiperactividad. El resultado es que el tálamo puede funcionar con más normalidad y el movimiento mejora. Pero la enfermedad — la pérdida de neuronas de dopamina — siguió avanzando durante los dos años desde la cirugía.”

(DBS does not stop Parkinson’s. Parkinson’s destroys neurons that produce dopamine. That continues happening, independently of DBS. What DBS does is send high-frequency electrical pulses — one hundred thirty times per second — to a structure inside the brain called the subthalamic nucleus. When Parkinson’s destroys the dopamine neurons, that nucleus becomes overactive — it fires signals too frequently, and that suppresses voluntary movement. DBS impulses turn off that overactivity. The result is that the thalamus can function more normally and movement improves. But the disease — the loss of dopamine neurons — continued advancing during the two years since surgery.)

Marisol processes this. “¿Entonces el DBS funciona, pero el Parkinson siguió avanzando y los parámetros ya no son suficientes para la enfermedad en este momento?”

(So DBS is working, but Parkinson’s continued advancing and the parameters are no longer sufficient for the disease at this moment?)

“Exactamente. Los parámetros que programamos hace dos años — la intensidad, la frecuencia, la anchura de los pulsos, cuáles contactos están activos — se calibraron para el estado de la enfermedad en ese momento. La enfermedad siguió su curso en los dos años desde entonces. Los parámetros que producían un control excelente hace dos años ya no son suficientes para el estado actual. El aparato no falló — la programación necesita actualizarse para coincidir con donde está la enfermedad ahora.”

(Exactly. The parameters we programmed two years ago — the intensity, the frequency, the pulse width, which contacts are active — were calibrated for the state of the disease at that time. The disease continued its course in the two years since then. The parameters that produced excellent control two years ago are no longer sufficient for the current state. The device did not fail — the programming needs to be updated to match where the disease is now.)

Ana reaches for an analogy she uses in these conversations. She asks Marisol whether Luciana wears reading glasses. Marisol says yes — for the last four years. Ana asks: when Luciana’s vision changed and the current glasses stopped working as well, did that mean the glasses were broken?

Marisol understands immediately. “No. Los ojos cambiaron y necesitó una graduación nueva.”

(No. The eyes changed and she needed a new prescription.)

“El DBS es lo mismo. El cerebro — específicamente, la parte del cerebro donde actúa el DBS — cambió porque la enfermedad avanzó. La ‘graduación’ que funcionaba hace dos años ya no es la correcta para el cerebro de hoy. El neurólogo va a ajustar esa graduación en la cita de programación. No es cirugía. Es un procedimiento ambulatorio de veinte a cuarenta minutos en que el neurólogo prueba combinaciones de parámetros y mide la respuesta motora de su mamá hasta encontrar la combinación que produce el mejor control para el estado actual.”

(DBS is the same. The brain — specifically, the part of the brain where DBS acts — changed because the disease advanced. The “prescription” that worked two years ago is no longer correct for the brain of today. The neurologist is going to adjust that prescription at the programming appointment. It is not surgery. It is an outpatient procedure of twenty to forty minutes where the neurologist tests combinations of parameters and measures your mother’s motor response until finding the combination that produces the best control for the current state.)

Ana schedules an urgent DBS programming visit for two weeks. She explains the process in concrete terms: Luciana will come in without her morning medication, and the neurologist will evaluate her motor function at each parameter setting, adjusting voltage, pulse width, frequency, and contact configuration. The visit will take thirty to forty minutes. She will likely leave with improved motor control same day.

Marisol closes the notebook. “Entonces no se rompió — necesitaba ajuste.” (So it did not break — it needed adjustment.)

“Correcto. Y el hecho de que la programación ya no sea suficiente después de dos años no significa que fue un fracaso. Significa que la enfermedad avanzó, como el Parkinson avanza, y el tratamiento se está adaptando a eso.”

(Correct. And the fact that the programming is no longer sufficient after two years does not mean it was a failure. It means the disease advanced, as Parkinson’s advances, and the treatment is adapting to that.)

At the programming visit two weeks later, voltage is increased from 3.0 to 3.5 volts on both sides, pulse width is widened from 60 to 90 microseconds on the right, and a second contact is added to the active configuration on the left. Luciana’s motor score improves from a pre-programming assessment of 31 to 20 in the same session. At the one-month follow-up, Marisol arrives without the notebook. Luciana arrived at the clinic without assistance from the parking garage. “Pensé que se había roto algo. Ahora entiendo que el Parkinson sigue avanzando y que el aparato se ajusta.”

The movement disorders clinic’s communication challenge

Ernesto stopped a medication because he read a description of a different phenomenon and recognized the word “tremors.” Roberto concluded his medication was failing because his comparison baseline was a subjective memory from a decade before treatment, not the objective measurement documented at intake. Marisol concluded a device had failed because she saw returning symptoms without a framework for distinguishing between disease progression and inadequate stimulation parameters.

In all three cases, the patient or family had a consistent internal model — one that generated a clear conclusion from available information. The conclusion was wrong because the model was missing a critical distinction: between two types of involuntary movement that look similar but are mechanistically opposite, between subjective memory and objective clinical documentation, between a device that has failed and a programming calibration that has been outpaced by disease progression.

The movement disorders clinic nurse who can name these distinctions clearly — without dismissing the patient’s observation, without moving past the patient’s model before repairing it — changes the outcome of the encounter before any clinical intervention. Ernesto needed the distinction between rest tremor and peak-dose dyskinesia explained in concrete terms with a timeline drawing. Roberto needed the difference between his ten-year-ago memory and his three-month-ago clinical baseline made visible on paper. Luciana and Marisol needed the distinction between device failure and programming obsolescence explained with an analogy that mapped the clinical concept onto an experience they already understood. Each explanation took approximately ten minutes. Each prevented a clinical outcome — continued under-medication, premature discontinuation, unnecessary surgery anxiety — that would have been far more costly in time, function, and trust.

Six practical phrases for movement disorders clinic conversations in Spanish

On carbidopa-levodopa and tremor misunderstanding: “Los movimientos ondulantes que vio en el video no son los temblores del Parkinson — se llaman discinesia, y ocurren cuando el nivel de la pastilla está en su punto más alto, no cuando está bajo. Son señales opuestas.” (The wave-like movements you saw in the video are not Parkinson’s tremors — they are called dyskinesia, and they occur when the pill’s level is at its highest point, not when it is low. They are opposite signals.)
On stopping dopamine replacement: “Cuando deja de tomar la pastilla, no aparece una enfermedad más leve — el nivel de dopamina baja al nivel que tienen sus neuronas restantes, que después de varios años ya no es el mismo nivel que sostenía el movimiento sin medicación.” (When you stop taking the pill, a milder disease does not appear — the dopamine level drops to the level your remaining neurons have, which after several years is no longer the same level that sustained movement without medication.)
On essential tremor baseline comparison: “La comparación correcta para la medicación es con cómo estaban sus manos hace tres meses, cuando empezamos el tratamiento — no con hace diez años. El temblor esencial progresa sin tratamiento; la medicación lo reduce desde donde está ahora.” (The correct comparison for the medication is with how your hands were three months ago, when we started treatment — not with ten years ago. Essential tremor progresses without treatment; the medication reduces it from where it is now.)
On primidone adjustment period: “Las primeras dos a cuatro semanas de primidona son las más difíciles porque el cuerpo se adapta al fenobarbital. Eso mejora. Y la dosis actual es una fracción de la dosis terapéutica — el beneficio completo llega cuando terminamos la titulación.” (The first two to four weeks of primidone are the most difficult because the body adapts to the phenobarbital. That improves. And the current dose is a fraction of the therapeutic dose — the full benefit arrives when we finish the titration.)
On DBS and disease progression: “El DBS no detiene el Parkinson — modula un circuito en el cerebro que está hiperactivo. La enfermedad sigue su curso. Cuando los síntomas vuelven, la primera pregunta es si la programación necesita actualizarse, no si el aparato se rompió.” (DBS does not stop Parkinson’s — it modulates a circuit in the brain that is overactive. The disease continues its course. When symptoms return, the first question is whether the programming needs to be updated, not whether the device broke.)
On DBS programming as ongoing calibration: “La programación del DBS es como la graduación de los lentes — no es una calibración única, sino algo que se actualiza cuando la visión cambia. El aparato está funcionando; la graduación que funcionaba hace dos años ya no coincide con el estado actual de la enfermedad.” (DBS programming is like a glasses prescription — it is not a one-time calibration, but something that is updated when the vision changes. The device is working; the prescription that worked two years ago no longer matches the current state of the disease.)

These three conversations share a common structure: a patient or family member who has observed something real, applied a reasonable inference from a flawed model, and arrived at a conclusion that, if uncorrected, would produce measurable clinical harm. The nurse’s role is not to dismiss the observation — the tremors in the video were real, the hands still shake, the symptoms did return — but to repair the model so the same observation produces the correct conclusion. Ernesto’s tremors are not being caused by the medication; they are what the medication was preventing. Roberto’s baseline comparison is ten years too early. The device is not broken; its programming is outdated.

The scenarios described here are available as practice conversations at ClinicaLingo, where the full clinical dialogue — including the patient presentation, the nurse’s mechanism explanation, and the Spanish phrases for both — is available for role-play with audio, tap-to-translate transcript, and targeted vocabulary review. Additional outpatient clinic conversations for Spanish-speaking patients are available in the neurology clinic nurses post and the multiple sclerosis clinic nurses post.